{
    "clinical_study": {
        "@rank": "79062", 
        "acronym": "STAR Extension", 
        "arm_group": {
            "arm_group_label": "Lu AE58054 60 mg (or 30 mg)", 
            "arm_group_type": "Experimental", 
            "description": "Lu AE58054 adjunct to 10 mg Donepezil. The dose to be maintained throughout the study."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive therapy to\n      donepezil in patients with mild-moderate AD."
        }, 
        "brief_title": "Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease", 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient has completed Visit 7 (Completion Visit) in the lead-in double-blind,\n             placebo controlled clinical studies 14861A/NCT01955161 or 14862A/NCT02006641.\n\n        Exclusion Criteria:\n\n          -  The patient has a moderate or severe ongoing adverse event from the lead-in study\n             considered a potential safety risk by the investigator.\n\n          -  The patient has experienced seizures before Completion Visit in the lead-in study.\n\n          -  The patient has evidence of clinically significant disease.\n\n          -  The patient's donepezil treatment is likely to be interrupted or discontinued during\n             the study.\n\n          -  The patient is receiving therapy with another acetylcholinesterase inhibitors (AChEI)\n             or memantine.\n\n        Other protocol-defined inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "1770", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079246", 
            "org_study_id": "14861B", 
            "secondary_id": "2013-000001-23"
        }, 
        "intervention": {
            "arm_group_label": "Lu AE58054 60 mg (or 30 mg)", 
            "description": "once daily, encapsulated tablets, orally", 
            "intervention_name": "Lu AE58054 60 mg (or 30 mg)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Donepezil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santa Ana", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92705"
                    }, 
                    "name": "US018"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 2", 
                        "country": "Czech Republic", 
                        "zip": "120 00"
                    }, 
                    "name": "CZ001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 6", 
                        "country": "Czech Republic", 
                        "zip": "160 00"
                    }, 
                    "name": "CZ002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rychnov nad Kneznou", 
                        "country": "Czech Republic", 
                        "zip": "516 01"
                    }, 
                    "name": "CZ005"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Czech Republic"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 32"
            }, 
            {
                "measure": "Number of withdrawals", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 32"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079246"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) total score", 
                "measure": "Change in cognition", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score", 
                "measure": "Change in global impression", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score", 
                "measure": "Change in functioning", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Change in Neuropsychiatric Inventory (NPI) total score", 
                "measure": "Change in behavioural disturbance", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Change in Mini Mental State Examination (MMSE)", 
                "measure": "Change in cognitive aspects of mental function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Columbia Suicide Severity Rating Scale (C-SSRS)", 
                "measure": "Risk of Suicidality Using C-SSRS Scores", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 28"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}